Q3 2024 Earnings Summary
- Strong performance of new products and biologicals: The company achieved about 20% organic growth in new products in Q3, with biologicals expected to be up double digits in EBITDA growth for 2024. These are the growth engines for the Crop Protection business and are expected to continue driving growth into 2025.
- Significant EBITDA growth in Crop Protection business: The Crop Protection segment saw its second consecutive quarter of volume growth, with over 30% EBITDA growth in Q3, driven by new technologies and biological investments. For 2025, they expect to outperform the flat industry with mid-single-digit volume growth, propelled by new technology.
- Strong free cash flow and shareholder returns: The company is generating robust cash flow, expecting $1.5 billion to $2 billion in free cash flow for the year, and returning approximately $1.5 billion to shareholders through buybacks and dividends, while investing in growth opportunities.
- Significant price declines in the Brazilian Crop Protection market, with prices down 18% in the third quarter due to intense competition and a flat to down market environment . This pressure may continue to impact margins and profitability.
- Substantial decrease in seed sales, with organic seed sales down 17% and seed volumes down 12% in Q3, primarily driven by a 20% reduction in Argentina's corn planted area . Additionally, North American seed prices declined by 25% year-over-year in Q3 due to elevated replant settlements caused by early season floods .
- The company reported an operating loss in the third quarter and adjusted full-year EBITDA guidance downward to $3.4 billion at the midpoint . With expectations of a flat Crop Protection market in 2025 and reliance on a significant fourth-quarter performance in Brazil, there are concerns about the company's growth prospects .
| Topic | Previous Mentions | Current Period | Trend |
|---|---|---|---|
Growth in biologicals as a key driver of volume and EBITDA | Previously accounted for around 65% of total Crop Protection (CP) growth (Q2), expected mid-20% growth (Q1), and projected to double operating EBITDA (Q4). | Continued emphasis on biologicals as a growth engine, with more than 20% volume growth and double-digit EBITDA expectations. | Consistently bullish, remains a major volume and profit driver. |
Advancement toward royalty neutrality and increasing royalty income | Previously highlighted 40%+ royalty income growth (Q2), $100 million royalty expense reduction for 2024 (Q1), and $200 million in benefits in 2023 (Q4). | Ahead of schedule on $100 million per year royalty improvements; plan for royalty income to exceed reduction by 2025. | Accelerating progress, shifting to a net technology seller. |
Significant cost improvements and productivity initiatives | Previously targeted $350-$450 million in annual benefits (Q2/Q1) and yielded $285 million savings in 2023 (Q4). | Expects $400 million cost improvements and $550 million in productivity benefits by 2025, partially offset by inflation. Achieved $160 million in controllable benefits in the smallest quarter. | Ongoing execution, positive impact on margins. |
Competition and pricing pressure in the Brazilian crop protection market | Faced 4% CP price decline in first half (Q2), stabilized generic imports but ongoing pressure (Q1), mention of generics and macro headwinds (Q4). | Prices down 18% in Brazil CP, reflecting a flat-to-down market and fierce competition; expect to finish the year with only mid-single-digit declines. | Continued pressure, but Corteva leverages differentiated products. |
Reduced corn planting in Argentina impacting seed volumes | Previously noted uncertainties (Q2), concern over leafhopper and corn stunt disease (Q1). Not mentioned in Q4. | 20% reduction in planted area, described as a real loss of seed business and margin. | Significant negative hit to volumes and profitability. |
Destocking concerns in crop protection channels, especially in Brazil and Europe | Previously stated that Brazil inventories neared normal and Europe destocking was largely behind (Q2/Q1). Continued mention in Q4 for Brazil. | Not explicitly emphasized this period, though indicated a well-supplied market. | Less explicit in Q3, situation appears to be improving. |
Increasing adoption of proprietary seed technologies | Previously noted 65% of U.S. acres in Enlist E3 (Q2), 60% in Q1, and 58% by Q4 2023. Tech like PowerCore Enlist and Pioneer Z-Series boosted royalties. | Higher royalty improvements credited to rapid Enlist E3 adoption; expect a strong 2025 transition to net royalty gains. | Continued expansion, core to margin and royalty growth. |
Uncertainty from potential regulatory changes (dicamba usage) | Previously highlighted dicamba label uncertainties for 2025 (Q2/Q1); no Q4 mention. | No mention in current period. | No new updates, remains a potential variable affecting Enlist demand. |
Continued margin expansion in the Seed business via new product introductions | Noted 420 bps margin expansion (Q2), a 300 bps jump in Q1, and ongoing new launches (Q4). | Rolled out hundreds of new hybrids and varieties for 2025, contributing to strong seed performance and share gains. | Consistent driver of seed margin improvements. |
Strong free cash flow generation supporting future growth and shareholder returns | Reached 50% FCF-to-EBITDA conversion (Q2), on track to ~$1.75B (Q1), and returned $1.2B to shareholders in 2023 (Q4). | Reaffirmed $1.5–$2.0B FCF outlook with ~45–50% conversion, planning ~$1.5B in buybacks and dividends. | Stable FCF, sustaining investments and shareholder returns. |
-
Confidence in 2025 Guidance
Q: How confident are you in the 2025 guidance?
A: While acknowledging that the 2025 guidance depends on several factors, especially the Crop Protection (CP) industry, management feels confident in delivering double-digit earnings growth and margin expansion. The seed business is on plan, and cost productivity is strong. Although the CP industry has faced challenges, signs point to stabilization. Their current view is based on a flattish CP market in 2025, and they have been candid in updating assumptions as industry conditions change. They believe the range provided reflects their best perspective at this time. -
2025 Guidance on Cost Deflation
Q: Why does 2025 cost deflation benefit seem low?
A: Of the $600 million gross benefit expected in 2025, about half is due to deflation in seed and Crop Protection costs. Seed deflation is a three-year journey, with benefits anticipated in 2025 through 2027. Management indicates that the current estimate aligns with their best perspective and it's early to predict possible upsides. They emphasize that a large part of this benefit is under their control, driven by cost management and productivity. -
EBIT Outlook Risks
Q: Are FX and CPC pricing risks to EBIT outlook?
A: Currency impacts, primarily from Brazil, are considered in the outlook, with management feeling comfortable with the current estimate of a $150 million impact. While predicting currency movements is challenging, they believe their assumptions are reasonable. They also express confidence regarding CPC pricing and other factors in the EBIT outlook, noting that achieving the higher end of their guidance would require overachieving on deliverables and some market strength. -
Crop Protection Expectations 2025
Q: What's baked into 2025 Cropchem guidance?
A: Management expects the CP market to be flat in 2025 but anticipates their business will perform better due to mid-single-digit volume growth driven by new technologies and biological investments. While pricing may be down low single digits, sales are expected to grow slightly, with new products leading the growth in volume. They believe their offerings will outperform the market despite the flat industry outlook. -
Argentina Seed Sales Impact
Q: How will Argentina seed sales affect earnings?
A: The company faces a 20% reduction in corn planting area in Argentina, from 8 million down to 6.5 million hectares, impacting a profitable and significant market where they hold an above-average market share of nearly 40%. This reduction represents lost sales rather than deferred business, affecting earnings. For 2025, they are prudently not assuming a significant rebound due to ongoing agronomic pressures but remain optimistic over the next few years. , -
Brazil Cropchem Pricing Decline
Q: Why did Brazil crop chemical prices drop 18%?
A: In a competitive and flat-to-down market, Brazil experienced an 18% price decline in crop chemicals for the quarter due to intense competition for volume. The company aims to hold share by focusing on products that drive value, particularly new and differentiated offerings. They expect to finish the year with mid-single-digit price declines overall and believe their strategy positions them well despite market pressures. -
New Products and Biologicals Performance
Q: How are new products and biologicals performing?
A: Biologicals are performing well, expected to achieve double-digit EBITDA growth for the year, serving as a strong complement to the synthetics business. New products saw about a 20% organic growth in Q3, continuing to perform above the market. Management anticipates that these offerings will continue to drive growth into 2025 and beyond, contributing significantly to the company's performance. -
Balance Sheet and Debt Consideration
Q: Would you consider taking on more debt?
A: Management's views remain consistent; they do not foresee meaningful changes in their capital structure. With strong free cash flow of $1.5 billion to $2 billion, they aim to invest in growth while maintaining capital returns to shareholders, and they regard their investment-grade rating as a strategic asset. They believe their current approach appropriately balances growth investments and shareholder returns. , -
North American Seed Price Drop
Q: Why was seed price down 25% year-over-year?
A: The 25% year-over-year drop in North American seed price reflects the timing of end-of-season settlements, specifically replant settlements that occurred later than usual. While it appears as a significant price concession, it's a normal part of the business influenced by the timing of when these settlements are recognized. This year, replants were within the normal range but settled in the third quarter rather than the second. -
$150 Million Cost Breakdown
Q: Can you break down the $150 million costs?
A: Of the $150 million in inflation and other costs, about 75% is in the Seed business, primarily related to trait transition costs in corn traits in North America. These costs are due to ramping up new technologies and incurring additional expenses until they reach a steady state. The company expects to manage these transition costs over the next couple of years as they complete the technology shift.